EMPOWER-Lung3: Evaluating Cemiplimab Plus Chemotherapy in Advanced NSCLC
Eduardo Santos, MD, FACP, FCCP, highlights key takeaways from the latest EMPOWER-LUNG03 data and discusses the impact of these findings on the treatment setting.
EP: 1.Immunotherapy-Based Strategies for NSCLC in the Neoadjuvant/Perioperative Setting
EP: 2.Advances in Neoadjuvant Immunotherapy for NSCLC: Conference Highlights 2023
EP: 3.Updates in Adjuvant Immunotherapy for NSCLC: Conference Highlights 2023
EP: 4.Immunotherapy-Based Treatment Strategies in Advanced NSCLC
Now Viewing
EP: 5.EMPOWER-Lung3: Evaluating Cemiplimab Plus Chemotherapy in Advanced NSCLC
EP: 6.Advancements in Squamous NSCLC Treatment: Subgroup Analysis from EMPOWER-Lung Trials
EP: 7.Advances in Dual Immunotherapy Approaches for NSCLC: Data Highlights 2023
EP: 8.NSCLC 2023 Data Updates: Shaping the Future Treatment Landscape
Related Videos
Related Content
